-
Ferring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of individualised vs.conventional recombinant follicular stimulating hormone dosing in Indian infertile patients
inFerring Pharmaceuticals announces results of the IRIS Study: A comparative analysis of…
-
U.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)
inU.S. FDA approves second drug product manufacturing facility for Adstiladrin® (nadofaragene firadenovec-vncg)…
-
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC patients
inFerring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating…
-
Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin
inFerring achieved record sales driven by Reproductive Medicine combined with the emergence…
PRESS RELEASE 2025
PRESS RELEASE 2025